AIMS: Our aims were to determine whether the information in the National Lung Cancer Audit database (LUCADA) is influenced by the completeness of reporting and to describe the current socio-demographics and survival of people with lung cancer in England. METHODS: Using national registry data as a gold standard we stratified NHS Trusts into quartiles on the basis of their patient ascertainment. We assessed the distribution of patient features across these quartiles using Cox and logistic regression. We then examined overall survival and access to treatment. RESULTS: We analysed data for 60,059 patients whose data were entered between 2004 and 2008. There was little variation in key patient features, treatment and median survival across quartiles of data completeness. Socio-economic disadvantage did not influence survival or access to surgery but was related to a decreased use of chemotherapy. CONCLUSION: Our findings suggest that LUCADA accurately describes people in England who are diagnosed with lung cancer and can therefore be used to drive health care improvements. Individual patient socio-economic status does not affect survival and has only a limited impact on access to treatment and so NHS Trust level factors should be studied to explain the previously published regional variations in these outcomes.
AIMS: Our aims were to determine whether the information in the National Lung Cancer Audit database (LUCADA) is influenced by the completeness of reporting and to describe the current socio-demographics and survival of people with lung cancer in England. METHODS: Using national registry data as a gold standard we stratified NHS Trusts into quartiles on the basis of their patient ascertainment. We assessed the distribution of patient features across these quartiles using Cox and logistic regression. We then examined overall survival and access to treatment. RESULTS: We analysed data for 60,059 patients whose data were entered between 2004 and 2008. There was little variation in key patient features, treatment and median survival across quartiles of data completeness. Socio-economic disadvantage did not influence survival or access to surgery but was related to a decreased use of chemotherapy. CONCLUSION: Our findings suggest that LUCADA accurately describes people in England who are diagnosed with lung cancer and can therefore be used to drive health care improvements. Individual patient socio-economic status does not affect survival and has only a limited impact on access to treatment and so NHS Trust level factors should be studied to explain the previously published regional variations in these outcomes.
Authors: Jean I Garcia-Gathright; Nicholas J Matiasz; Carlos Adame; Karthik V Sarma; Lauren Sauer; Nova F Smedley; Marshall L Spiegel; Jennifer Strunck; Edward B Garon; Ricky K Taira; Denise R Aberle; Alex A T Bui Journal: Comput Biol Med Date: 2017-11-03 Impact factor: 4.589
Authors: Jean I Garcia-Gathright; Nicholas J Matiasz; Edward B Garon; Denise R Aberle; Ricky K Taira; Alex A T Bui Journal: IEEE EMBS Int Conf Biomed Health Inform Date: 2016-04-21
Authors: Naomi Beck; Fieke Hoeijmakers; Erwin M Wiegman; Hans J M Smit; Franz M Schramel; Willem H Steup; Ad F T M Verhagen; Wilhelmina H Schreurs; Michel W J M Wouters Journal: J Thorac Dis Date: 2018-10 Impact factor: 2.895
Authors: Barbara Iyen-Omofoman; Richard B Hubbard; Chris J P Smith; Emily Sparks; Emma Bradley; Alison Bourke; Laila J Tata Journal: BMC Public Health Date: 2011-11-10 Impact factor: 3.295
Authors: Derek Grose; Graham Devereux; Louise Brown; Richard Jones; Dave Sharma; Colin Selby; David S Morrison; Kirsty Docherty; David McIntosh; Penny McElhinney; Marianne Nicolson; Donald C McMillan; Robert Milroy Journal: Lung Cancer Int Date: 2014-03-05